<<Disclaimer: Verify this information before applying it to your situation.>>

Glucagon-like peptide-2 (GLP-2) and R-spondin1 both promise to 
regenerate and heal the intestinal mucosa.  R-spondin1 (NU206, 
Nuvelo, Inc. http://www.nuvelo.com ) is a protein of very recent 
discovery, and research and publication on R-spondin1 is limited with 
no human trials to date.  R-spondin1 is potentially a much more 
potent stimulator of intestinal growth than GLP-2.  However, there 
has been much research on GLP-2.  A wealth of research information 
and publications about GLP-2 can be found at:  
http://www.glucagon.com/glp-2.htm

Teduglutide, a proprietary compound of NPS Pharmaceuticals, is an 
analog of GLP-2, a naturally occurring hormone that regulates the 
growth, proliferation and maintenance of cells lining the 
gastrointestinal tract. Teduglutide differs from GLP-2 by a change in 
one amino acid which gives it greater resistance to protease enzyme 
breakdown than GLP-2. ( 
http://www.npsp.com/drug_development/dd_alx0600.php )

Some selected GLP-2 publications are given below:

----------
Discovering the Intestinal Growth Effects of GLP-2:

Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7911-6.
Induction of intestinal epithelial proliferation by glucagon-like 
peptide 2.
Drucker DJ, Erlich P, Asa SL, Brubaker PL.
Free full text (PDF):
http://www.pnas.org/cgi/reprint/93/15/7911

----------
Intestinal Permeability and GLP-2:

Gut. 2000 Jul;47(1):112-9.
Glucagon-like peptide-2 enhances intestinal epithelial barrier 
function of both transcellular and paracellular pathways in the 
mouse.
Benjamin MA, McKay DM, Yang PC, Cameron H, Perdue MH.
Free full text:
http://gut.bmjjournals.com/cgi/content/full/47/1/112

Am J Physiol Gastrointest Liver Physiol. 2003 Jun;284(6):G905-12. 
Glucagon-like peptide-2-enhanced barrier function reduces 
pathophysiology in a model of food allergy.
Cameron HL, Yang PC, Perdue MH.
Free full text:
http://ajpgi.physiology.org/cgi/content/full/284/6/G905

----------
Human Trials of Teduglutide:

Gut. 2005 Sep;54(9):1224-31.
Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-
like peptide 2 analogue, improves intestinal function in short bowel 
syndrome patients.
Jeppesen PB, Sanguinetti EL, Buchman A, Howard L, Scolapio JS, 
Ziegler TR, Gregory J, Tappenden KA, Holst J, Mortensen PB.
Abstract:
http://gut.bmjjournals.com/cgi/content/abstract/54/9/1224

New Study Shows Novel Therapy May Produce Early Remission In Crohn's 
Patients
Article Date: 23 May 2006 
http://www.medicalnewstoday.com/medicalnews.php?newsid=43803

* * *

*Support summarization of posts, reply to the SENDER not the CELIAC List*
Archives are at: Http://Listserv.icors.org/SCRIPTS/WA-ICORS.EXE?LIST=CELIAC